Back to Search Start Over

Development of Imiquimod-induced HaCaT-THP-1 co-culture for modeling of psoriasis.

Authors :
Váradi J
Oláh B
Hosszú D
Fenyvesi F
Remenyik J
Homoki J
Nagy B Jr
Fejes Z
Bácskay I
Klusóczki Á
Source :
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences [Eur J Pharm Sci] 2024 Sep 01; Vol. 200, pp. 106846. Date of Electronic Publication: 2024 Jul 05.
Publication Year :
2024

Abstract

Psoriasis is one of the most prevalent and chronic inflammatory disease of the skin, associated with disrupted barrier function. Currently, a widely accepted, generally usable cell culture model has not been developed yet. In the present work, we aimed to establish a co-culture model with human keratinocyte (HaCaT) and human monocyte cells (THP-1) induced by Imiquimod (IMQ), which acts on the TLR7 receptor. The role of TLR7 expressed on THP-1 cells was confirmed by immunofluorescence staining of NF-κB activation. Chloroquine (CH) was used as a receptor inhibitor, in the presence or absence of which the NF-κB pathway was activated. We determined the most effective proliferation-stimulating IMQ concentration by RTCA method and the hyperproliferative effect was investigated by wound-healing test. The effect of IMQ was compared with the effects of the anthocyanin (AC) components from the anti-inflammatory sour cherry extract that we have already studied. We found that IMQ significantly increased the migration rate however, the combined treatment resulted in a decreased migration rate compared to the IMQ treatment alone. Inflammatory cytokines were measured from the supernatant of co-culture by ELISA. During the development of the co-culture intended to model psoriasis, we confirmed the induction effect of IMQ and in the case of AC treatment, we supported the stabilizing effect of the barrier.<br />Competing Interests: Declaration of competing interest We wish to confirm that there is no conflict of interest associated with this publication.<br /> (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1879-0720
Volume :
200
Database :
MEDLINE
Journal :
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Publication Type :
Academic Journal
Accession number :
38972610
Full Text :
https://doi.org/10.1016/j.ejps.2024.106846